Article

March 30, 2015

Palliative Care Improves Survival in Advanced Cancer, Studies Report

Two studies, published last week in Journal of Clinical Oncology, report improved survival as well as reduced caregiver burden following early initiation of palliative care in advanced cancer patients.

Early initiation of palliative care (PC) interventions improves survival and caregiver burden in advanced cancer, according to 2 studies published online March 23 in the Journal of Clinical Oncology.

Marie A. Bakitas, DNSc, CRNP, from the University of Alabama at Birmingham, and colleagues conducted a randomized trial involving 207 patients with advanced cancer. Participants were randomized to receive an in-person PC consultation, structured PC telehealth nurse coaching sessions, and monthly follow-up, early after enrollment or three months later. The researchers found that patient-reported outcomes did not differ significantly after enrollment or before death. One-year survival rates were 63 and 48% in the early and delayed groups, respectively (P = 0.038).

Read the report on MedicalXpress:

http://bit.ly/1GGURCZ

Related Videos

Screenshot of an interview with Shaun McKenzie, MD

Screenshot of an interview with Shaun McKenzie, MD

Screenshot of an interview with Rohan Garje, MD

Susan Escudier, MD, FACP

Sabarish Ayyappan, MD

Susan Escudier, MD, FACP

Screenshot of an interview with Evangelia Vlachou, MD

Screenshot of an interview with Barry Goy, MD

Debra Patt, MD, PhD, MBA, MPH

Related Content

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

lung cancer | Image credit: Crystal light - stock.adobe.com

March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.

Karen Winkfield, MD, PhD

March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD

Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.

Related Content

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

lung cancer | Image credit: Crystal light - stock.adobe.com

March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.

Karen Winkfield, MD, PhD

March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD

Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions